

# **Guidance for Industry**

## **STABILITY TESTING OF NEW BIOTECHNOLOGICAL/BIOLOGICAL VETERINARY MEDICINAL PRODUCTS VICH GL17**

### **FINAL GUIDANCE**

This final document provides guidance to applicants regarding the type of stability data that should be provided in support of new animal drug applications (referred to as marketing applications in the guidance) for approval of veterinary biotechnological/biological products submitted to the European Union, Japan and the United States. It is understood that during the review and evaluation process, continuing updates of initial stability data may occur.

Comments and suggestions regarding this document should be submitted to the Division of Dockets Management, (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

For questions regarding this final document, contact Mai Huynh, Center for Veterinary Medicine, (HFV-142), Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, 240-276-8273, [Mai.huynh@fda.hhs.gov](mailto:Mai.huynh@fda.hhs.gov).

---

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Veterinary Medicine  
March 26, 2001**

---

**VICH GL17 (STABILITY 4)  
June 2000  
For implementation at Step 7**

# STABILITY TESTING OF NEW BIOTECHNOLOGICAL/BIOLOGICAL VETERINARY MEDICINAL PRODUCTS

---

Recommended for Implementation  
at Step 7 of the VICH Process  
on 15 June 2000  
by the VICH Steering Committee

THIS GUIDANCE HAS BEEN DEVELOPED BY THE APPROPRIATE VICH EXPERT WORKING GROUP ON THE BASIS OF THE ICH GUIDANCES ON THE SAME SUBJECT AND WAS SUBJECT TO CONSULTATION BY THE PARTIES, IN ACCORDANCE WITH THE VICH PROCESS. AT STEP 7 OF THE PROCESS THE FINAL DRAFT IS RECOMMENDED FOR ADOPTION TO THE REGULATORY BODIES OF THE EUROPEAN UNION, JAPAN AND USA.

**STABILITY TESTING OF  
NEW BIOTECHNOLOGICAL/BIOLOGICAL  
VETERINARY MEDICINAL PRODUCTS**

<b>I. PREAMBLE (1)</b>	<b>4</b>
<b>II. SCOPE OF THE ANNEX (2)</b>	<b>4</b>
<b>III. TERMINOLOGY (3)</b>	<b>5</b>
<b>IV. SELECTION OF BATCHES (4)</b>	<b>5</b>
A. Drug Substance (Bulk Material) (4.1)	5
B. Intermediates (4.2)	5
C. Drug Product (Finished Product) (4.3)	5
D. Sample Selection (4.4)	6
E. Container/Closure (4.5)	6
<b>V. STABILITY-INDICATING PROFILE (5)</b>	<b>6</b>
A. Protocol (5.1)	7
B. Potency (5.2)	7
C. Purity and Molecular Characterization (5.3)	7
D. Other Product Characteristics (5.4)	8
<b>VI. STORAGE CONDITIONS (6)</b>	<b>8</b>
A. Temperature (6.1)	8
B. Humidity (6.2)	9
C. Accelerated and Stress Conditions (6.3)	9
D. Light (6.4)	9
<b>VII. USAGE CONDITIONS (7)</b>	<b>9</b>
A. Stability after First Opening or Reconstitution of Freeze-Dried Product (7.1)	9
B. Multiple-Dose Vials (7.2)	9
<b>VIII. TESTING FREQUENCY (8)</b>	<b>9</b>
<b>IX. SPECIFICATIONS (9)</b>	<b>10</b>
<b>X. LABELING (10)</b>	<b>10</b>
<b>XI. GLOSSARY (11)</b>	<b>10</b>
Conjugated Product	10
Degradation Product	10
Impurity	11
Intermediate	11
Manufacturing Scale Production	11
Pilot-Plant Scale	11

## **STABILITY TESTING OF NEW BIOTECHNOLOGICAL/BIOLOGICAL VETERINARY MEDICINAL PRODUCTS**

***This final guidance document represents the agency's current thinking on stability testing of new biotechnological/biological veterinary medicinal products. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of applicable statutes and regulations.***

### **I. PREAMBLE (1)**

The guidance stated in the VICH harmonized tripartite guidance entitled "Stability Testing of New Veterinary Drug Substances and Medicinal Products" (GL3)<sup>1</sup> applies in general to new biotechnological/biological products. However, biotechnological/biological products have distinguishing characteristics to which consideration should be given in any well-defined testing program designed to confirm their stability during the intended storage period. For such products in which the active components are typically well-characterized proteins and/or polypeptides, maintenance of molecular conformation and, hence, of biological activity, is dependent on noncovalent as well as covalent forces. The products are particularly sensitive to environmental factors such as temperature changes, oxidation, light, ionic content, and shear. To ensure maintenance of biological activity and to avoid degradation, stringent conditions for their storage are usually necessary.

The evaluation of stability may necessitate complex analytical methodologies. Assays for biological activity, where applicable, should be part of the pivotal stability studies. Appropriate physicochemical, biochemical, and immunochemical methods for the analysis of the molecular entity and the quantitative detection of degradation products should also be part of the stability program whenever purity and molecular characteristics of the product permit use of these methodologies.

With these concerns in mind, the applicant should develop the proper supporting stability data for a new biotechnological/biological product and consider many external conditions that can affect the product's potency, purity, and quality. Primary data to support a requested storage period for either drug substance or drug product should be based on long-term, real-time, real-condition stability studies. Thus, the development of a proper long-term stability program becomes critical to the successful development of a commercial product. The purpose of this document is to give guidance to applicants regarding the type of stability studies that should be provided in support of marketing applications. It is understood that during the review and evaluation process, continuing updates of initial stability data may occur.

### **II. SCOPE OF THE ANNEX (2)**

The guidance stated in this annex applies to products composed of well-characterized proteins and polypeptides, and their derivatives which are isolated from tissues, body fluids, cell cultures, or produced using recombinant deoxyribonucleic acid (r-DNA) technology. Thus, the document covers the generation and submission of stability data for products such as cytokines, growth hormones and growth factors, insulins, monoclonal antibodies, and those vaccines which consist of well-characterized proteins or polypeptides even when chemically synthesized. This document

---

<sup>1</sup> A copy of the guidance document entitled "Stability Testing of New Veterinary Drug Substances and Medicinal Products" (#73) (GL3) may be obtained on the Internet from the CVM Home Page at <http://www.fda.gov/AnimalVeterinary/default.htm>.

dose not cover antibiotics, heparins, vitamins, cell metabolites, DNA products, allergenic extracts, conventional vaccines, cells, whole blood, and cellular blood components.

### **III. TERMINOLOGY (3)**

For the basic terms used in this annex, the reader is referred to the "Glossary" in "Stability Testing of New Veterinary Drug Substances and Medicinal Products, GL3 (Guidance for Industry #73)," (<http://www.fda.gov/AnimalVeterinary/default.htm>.) However, because manufacturers of biotechnological/biological products sometimes use traditional terminology, traditional terms are specified in parentheses to assist the reader. A supplemental glossary is also included that explains certain terms used in the production of biotechnological/biological products.

### **IV. SELECTION OF BATCHES (4)**

#### **A. Drug Substance (Bulk Material) (4.1)**

Where bulk material is to be stored after manufacture, but before formulation and final manufacturing, stability data should be provided on at least three batches for which manufacture and storage are representative of the manufacture scale of production. A minimum of six months stability data at the time of submission should be submitted in cases where storage periods greater than six months are requested. For drug substances with storage periods of less than six months, the minimum amount of stability data in the initial submission should be determined on a case-by-case basis. Data from pilot-plant scale batches of drug substance produced at a reduced scale of fermentation and purification should be provided at the time the dossier is submitted to the regulatory agencies with a commitment to place the first three manufacturing scale batches into the long-term stability program after approval.

The overall quality of the batches of drug substance placed on formal stability studies should be representative of the quality of the material used in preclinical and clinical studies and of the quality of the material to be made at manufacturing scale. In addition, the drug substance (bulk material) made at pilot-plant scale should be produced by a process and stored under conditions representative of that used for the manufacturing scale. The drug substance entered into the stability program should be stored in containers that properly represent the actual holding containers used during manufacture. Containers of reduced size may be acceptable for drug substance stability testing provided that they are constructed of the same material and use the same type of container/closure system that is intended to be used during manufacture.

#### **B. Intermediates (4.2)**

During manufacture of biotechnological/biological products, the quality and control of certain intermediates may be critical to the production of the final product. In general, the manufacturer should identify intermediates and generate in-house data and process limits that assure their products stability within the bounds of the developed process. Although the use of pilot-plant scale data is permissible, the manufacturer should establish the suitability of such data using the manufacturing scale process.

#### **C. Drug Product (Finished Product) (4.3)**

Stability information should be provided on at least three batches of finished product representative of that which will be used at manufacturing scale. Where possible, batches of finished product included in stability testing should be derived from different batches of bulk material. A minimum of six months data at the time of submission should be submitted in cases where storage periods greater than six months are requested. For drug products with storage periods of less than six months, the minimum amount of stability data in the initial submission should be determined on a case-by-case basis. Product expiration dating should be based upon

the actual data submitted in support of the application. Because dating is based upon the real-time/real-temperature data submitted for review, continuing updates of initial stability data should occur during the review and evaluation process. The quality of the finished product placed on stability studies should be representative of the quality of the material used in the preclinical and clinical studies. Data from pilot-plant scale batches of drug product may be provided at the time the dossier is submitted to the regulatory authorities with a commitment to place the first three manufacturing scale batches into the long-term stability program after approval. Where pilot-plant scale batches were submitted to establish the dating for a product and, in the event that the product produced at manufacturing scale does not meet those long-term stability specifications throughout the dating period or is not representative of the material used in preclinical and clinical studies, the applicant should notify the appropriate regulatory authorities to determine a suitable course of action.

#### **D. Sample Selection (4.4)**

Where one product is distributed in batches differing in fill volume (e.g., 1 milliliter (ml), 2 ml, or 10 ml), unitage (e.g., 10 units, 20 units, or 50 units), or mass (e.g., 1 milligram (mg), 2 mg, or 5 mg), samples to be entered into the stability program may be selected on the basis of a matrix system and/or by bracketing.

Matrixing, i.e., the statistical design of a stability study in which different fractions of samples are tested at different sampling points, should only be applied when appropriate documentation is provided that confirms that the stability of the samples tested represents the stability of all samples. The differences in the samples for the same drug product should be identified as, for example, covering different batches, different strengths, different sizes of the same closure, and, possibly, in some cases, different container/closure systems. Matrixing should not be applied to samples with differences that may affect stability, such as different strengths and different containers/closures, where it cannot be confirmed that the products respond similarly under storage conditions.

Where the same strength and exact container/closure system is used for three or more fill contents, the manufacturer may elect to place only the smallest and largest container size into the stability program, i.e., bracketing. The design of a protocol that incorporates bracketing assumes that the stability of the intermediate condition samples are represented by those at the extremes. In certain cases, data may be needed to demonstrate that all samples are properly represented by data collected for the extremes.

#### **E. Container/Closure (4.5)**

Changes in the quality of the product may occur due to the interactions between the formulated biotechnological/biological product and container/closure. Where the lack of interactions cannot be excluded in liquid products (other than sealed ampoules), stability studies should include samples maintained in the inverted or horizontal position (i.e., in contact with the closure), as well as in the upright position, to determine the effects of the closure on product quality. Data should be supplied for all different container/closure combinations that will be marketed.

### **V. STABILITY-INDICATING PROFILE (5)**

On the whole, there is no single stability-indicating assay or parameter that profiles the stability characteristics of a biotechnological/biological product. Consequently, the manufacturer should propose a stability-indicating profile that provides assurance that changes in the identity, purity, and potency of the product will be detected.

At the time of submission, applicants should have validated the methods that comprise the stability-indicating profile, and the data should be available for review. The determination of

which tests should be included will be product-specific. The items emphasized in the following subsections are not intended to be all-inclusive, but represent product characteristics that should typically be documented to demonstrate product stability adequately.

### **A. Protocol (5.1)**

The dossier accompanying the application for marketing authorization should include a detailed protocol for the assessment of the stability of both drug substance, when applicable, and drug product in support of the proposed storage conditions and expiration dating periods. The protocol should include all necessary information that demonstrates the stability of the biotechnological/biological product throughout the proposed expiration dating period including, for example, well-defined specifications and test intervals. The statistical methods that should be used are described in the tripartite guidance on stability.

### **B. Potency (5.2)**

When the intended use of a product is linked to a definable and measurable biological activity, testing for potency should be part of the stability studies. For the purpose of stability testing of the products described in this guidance, potency is the specific ability or capacity of a product to achieve its intended effect. It is based on the measurement of some attribute of the product and is determined by a suitable quantitative method. In general, potencies of biotechnological/biological products tested by different laboratories can be compared in a meaningful way only if expressed in relation to that of an appropriate reference material. For that purpose, a reference material calibrated directly or indirectly against the corresponding national or international reference material should be included in the assay if possible.

Potency studies should be performed at appropriate intervals as defined in the stability protocol and the results should be reported in units of biological activity calibrated, whenever possible, against nationally or internationally recognized standards. Where no national or international reference standards exist, the assay results may be reported in in-house derived units using a characterized reference material.

In some biotechnological/biological products, potency is dependent upon the conjugation of the active ingredient(s) to a second moiety or binding to an adjuvant. Dissociation of the active ingredient(s) from the carrier used in conjugates or adjuvants should be examined in real-time/real-temperature studies (including conditions encountered during shipment). The assessment of the stability of such products may be difficult because, in some cases, *in vitro* tests for biological activity and physicochemical characterization are impractical or provide inaccurate results. Appropriate strategies (e.g., testing the product before conjugation/binding, assessing the release of the active compound from the second moiety, *in vivo* assays) or the use of an appropriate surrogate test should be considered to overcome the inadequacies of *in vitro* testing. In many cases, the validated *in vivo* potency test will indicate that there has been no significant dissociation.

### **C. Purity and Molecular Characterization (5.3)**

For the purpose of stability testing of the products described in this guidance, purity is a relative term. Because of the effect of glycosylation, deamidation, or other heterogeneities, the absolute purity of a biotechnological/biological product is extremely difficult to determine. Thus, the purity of a biotechnological/biological product should be typically assessed by more than one method and the purity value derived is method-dependent. For the purpose of stability testing, tests for purity should focus on methods for determination of degradation products.

The degree of purity, as well as the individual and total amounts of degradation products of the biotechnological/biological product entered into the stability studies, should be reported and documented whenever possible and necessary. Limits of acceptable degradation should be

## *Contains Nonbinding Recommendations*

derived from the analytical profiles of batches of the drug substance and drug product used in the preclinical and clinical studies.

The use of relevant physicochemical, biochemical, and immunochemical analytical methodologies should permit a comprehensive characterization of the drug substance and/or drug product (e.g., molecular size, charge, hydrophobicity) and the accurate detection of degradation changes that may result from deamidation, oxidation, sulfoxidation, aggregation, or fragmentation during storage. As examples, methods that may contribute to this include electrophoresis (SDS-polyacrylamide gel electrophoresis, immunoelectrophoresis, Western blot, isoelectrofocusing), high-resolution chromatography (e.g., reversed-phase chromatography, gel filtration, ion exchange, affinity chromatography), and peptide mapping.

Wherever significant qualitative or quantitative changes indicative of degradation product formation are detected during long-term, accelerated, and/or stress stability studies, consideration should be given to potential hazards and to the need for characterization and quantification of degradation products within the long-term stability program. Acceptable limits should be proposed and justified, taking into account the levels observed in material used in preclinical and clinical studies.

For substances that cannot be properly characterized or products for which an exact analysis of the purity cannot be determined through routine analytical methods, the applicant should propose and justify alternative testing procedures.

### **D. Other Product Characteristics (5.4)**

The following product characteristics, though not specifically relating to biotechnological/biological products, should be monitored and reported for the drug product in its final container:

Visual appearance of the product (color and opacity for solutions/suspensions; color, texture, and dissolution time for powders), visible particulates in solutions or after the reconstitution of powders or lyophilized cakes, pH, and moisture level of powders and lyophilized products.

Sterility testing or alternatives (e.g., container/closure integrity testing) should be performed at a minimum initially and at the end of the proposed shelf life.

Additives (e.g., stabilizers, preservatives) or excipients may degrade during the dating period of the drug product. If there is any indication during preliminary stability studies that reaction or degradation of such materials adversely affects the quality of the drug product, these items may need to be monitored during the stability program.

The container/closure has the potential to affect the product adversely and should be carefully evaluated.

## **VI. STORAGE CONDITIONS (6)**

### **A. Temperature (6.1)**

Because most finished biotechnological/biological products need precisely defined storage temperatures, the storage conditions for the real-time/real-temperature stability studies may be confined to the proposed storage temperature.

## **B. Humidity (6.2)**

Biotechnological/biological products are generally distributed in containers protecting them against humidity. Therefore, where it can be demonstrated that the proposed containers (and conditions of storage) afford sufficient protection against high and low humidity, stability tests at different relative humidities can usually be omitted. Where humidity-protecting containers are not used, appropriate stability data should be provided.

## **C. Accelerated and Stress Conditions (6.3)**

As previously noted, the expiration dating should be based on real-time/real-temperature data. However, it is strongly suggested that studies be conducted on the drug substance and drug product under accelerated and stress conditions. Studies under accelerated conditions may provide useful support data for establishing the expiration date, provide product stability information for future product development (e.g., preliminary assessment of proposed manufacturing changes such as change in formulation, scale-up), assist in validation of analytical methods for the stability program, or generate information that may help elucidate the degradation profile of the drug substance or drug product. Studies under stress conditions may be useful in determining whether accidental exposures to conditions other than those proposed (e.g., during transportation) are deleterious to the product and also for evaluating which specific test parameters may be the best indicators of product stability. Studies of the exposure of the drug substance or drug product to extreme conditions may help to reveal patterns of degradation; if so, such changes should be monitored under proposed storage conditions. Although the tripartite guidance on stability describes the conditions of the accelerated and stress study, the applicant should note that those conditions may not be appropriate for biotechnological/biological products. Conditions should be carefully selected on a case-by-case basis.

## **D. Light (6.4)**

Applicants should consult the appropriate regulatory authorities on a case-by-case basis to determine guidance for testing.

# **VII. USAGE CONDITIONS (7)**

## **A. Stability after First Opening or Reconstitution of Freeze-Dried Product (7.1)**

The stability of freeze-dried products after their reconstitution should be demonstrated for the conditions and the maximum storage period specified on containers, packages, and/or package inserts. Such labeling should be in accordance with relevant national/regional requirements.

## **B. Multiple-Dose Vials (7.2)**

In addition to the standard data necessary for a conventional single-use vial, the applicant should demonstrate that the closure used with a multiple-dose vial is capable of withstanding the conditions of repeated insertions and withdrawals so that the product retains its full potency, and quality for the maximum period specified in the instructions-for-use on containers, packages, and/or package inserts. Such labeling should be in accordance with relevant national/regional requirements.

# **VIII. TESTING FREQUENCY (8)**

The shelf-lives of biotechnological/biological products may vary from days to several years. Thus, it is difficult to draft uniform guidances regarding the stability study duration and testing frequency that would be applicable to all types of biotechnological/biological products. With only

a few exceptions, however, the shelf-lives for existing products and potential future products will be within the range of 0.5 to five years. Therefore, the guidance is based upon expected shelf-lives in that range. This takes into account the fact that degradation of biotechnological/biological products may not be governed by the same factors during different intervals of a long storage period.

When shelf-lives of less than one year are expected, the real-time stability studies should be conducted monthly for the first three months and at three month intervals thereafter. For products with expected shelf-lives of greater than one year, the studies should be conducted every three months during the first year of storage, every six months during the second year, and annually thereafter.

While the testing intervals listed above may be appropriate in the pre-approval or pre-license stage, reduced testing may be appropriate after approval or licensure where data are available that demonstrate adequate stability. Where data exist that indicate the stability of a product is not compromised, the applicant is encouraged to submit a protocol that supports elimination of specific test intervals (e.g., nine-month testing) for post-approval/post-licensure, long-term studies. If *in vivo* potency tests are part of the stability protocol, the omission of some testing points for those tests should be justified.

## **IX. SPECIFICATIONS (9)**

Although biotechnological/biological products may be subject to significant losses of activity, physicochemical changes, or degradation during storage, international and national regulations have provided little guidance with respect to distinct release and end of shelf-life specifications. Recommendations for maximum acceptable losses of activity, limits for physicochemical changes, or degradation during the proposed shelf-life have not been developed for individual types or groups of biotechnological/biological products but are considered on a case-by-case basis. Each product should retain its specifications within established limits for safety, purity, and potency throughout its proposed shelf-life. These specifications and limits should be derived from all available information using the appropriate statistical methods. The use of different specifications for release and expiration should be supported by sufficient data to demonstrate that the clinical performance is not affected, as discussed in the tripartite guidance on stability.

## **X. LABELING (10)**

For most biotechnological/biological drug substances and drug products, precisely defined storage temperatures are recommended. Specific recommendations should be stated, particularly for drug substances and drug products that cannot tolerate freezing. These conditions, and where appropriate, recommendations for protection against light and/or humidity, should appear on containers, packages, and/or package inserts. Such labeling should be in accordance with relevant national and regional requirements.

## **XI. GLOSSARY (11)**

### **Conjugated Product**

A conjugated product is made up of an active ingredient (e.g., peptide, carbohydrate) bound covalently or noncovalently to a carrier (e.g., protein, peptide, inorganic mineral) with the objective of improving the efficacy or stability of the product.

### **Degradation Product**

A molecule resulting from a change in the drug substance (bulk material) brought about over time. For the purpose of stability testing of the products described in this guidance, such changes could occur as a result of processing or storage (e.g., by deamidation, oxidation,

aggregation, proteolysis). For biotechnological/biological products, some degradation products may be active.

### **Impurity**

Any component of the drug substance (bulk material) or drug product (finished product) that is not the chemical entity defined as the drug substance, an excipient, or other additives to the drug product.

### **Intermediate**

For biotechnological/biological products, a material produced during a manufacturing process that is not the drug substance or the drug product but whose manufacture is critical to the successful production of the drug substance or the drug product. Generally, an intermediate will be quantifiable and specifications will be established to determine the successful completion of the manufacturing step before the manufacturing process is continued. This includes material that may undergo further molecular modification or be held for an extended period before further processing.

### **Manufacturing Scale Production**

Manufacture at the scale typically encountered in a facility intended for product production for marketing.

### **Pilot-Plant Scale**

The production of the drug substance or drug product by a procedure fully representative of and simulating that to be applied at manufacturing scale. The methods of cell expansion, harvest, and product purification should be identical except for the scale of production.